NCT00647764已完成1 期
Phase 1 Study Of SNX-5422 Mesylate In Adults With Refractory Solid Tumor Malignancies And Lymphomas
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Esanex Inc.
- 入组人数
- 32
- 试验地点
- 1
- 主要终点
- MTD, safety and toxicity
研究概览
简要总结
Hsp90 is a chemical in the body that is involved in promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90. It is being evaluated for safety and efficacy in patients with cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Solid tumors or lymphoid malignancies refractory to standard therapy
- •measurable disease
- •recovery to Grade < 1 toxicity due to prior adverse event or chemotherapy
- •no chemotherapy within 4 weeks of entering study
- •Age > 18 years
- •Karnofsy >= 60%
- •Life expectancy > 3 months
- •normal or adequate organ and marrow function
排除标准
- •receiving other investigational agents
- •brain metastases
- •uncontrolled medical illness
- •HIV+ receiving combination antiretroviral therapy
- •significant GI disease
研究组 & 干预措施
Single Arm
Experimental
干预措施: SNX-5422 Mesylate Hsp90 inhibitor (Drug)
结局指标
主要结局
MTD, safety and toxicity
时间窗: continuous
次要结局
- pharmacokinetic profile of SNX-5422(first cycle)
- tumor response measured by X-rays or scans(after every 2 cycles)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
SNX-5422 to Treat Solid Tumor Cancers and LymphomasNeoplasmsLymphomaNCT00644072National Cancer Institute (NCI)33
终止
1 期
Safety and Efficacy of SNX-5422 in Human Epidermal Growth Factor Receptor 2 (HER2) Positive CancersCancerNCT01848756Esanex Inc.15
已完成
1 期
Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Hematological MalignanciesCancerNCT01635712Esanex Inc.10
已完成
1 期
Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Solid Tumor MalignanciesCancerNCT01611623Esanex Inc.9
已完成
1 期
Safety And Pharmacology Study Of SNX-5422 Mesylate In Subjects With Refractory Solid Tumor MalignanciesCancerNCT00506805Esanex Inc.44